Gerald Schulman
Last active: 2/26/2014

Profile

I have been involved in clinical trials at Vanderbilt University for over two decades and I serve as the co-directorof the Clinical Trials Center at Vanderbilt (CTC). I was one of the investigators who  participated in designing then HEMO Study and the AASK Study.  I was a co-investigator in the MDRD (Phase III) and AASK studies and I was the principal investigator from Vanderbilt for the HEMO Study.

We have participated or led studies in this area.  Included among our efforts are studies with ESA,   novel substances to prevent progression of CKD (I designed and was Chair of the Steering Committeefor the EPPIC Study examining the effect of AST-120 on progression of CKD), the use of angiotensinreceptor blockers inpreventing progression of CKD and participation in the Frequent Dialysis Network.

The CTC of the nephrology division is poised to be able to design trials in patients evaluatinginterventionswith CKD.

 

Publications

The following timeline graph is generated from all co-authored publications.

Featured publications are shown below:

  1. AST-120 for the management of progression of chronic kidney disease. Schulman G, Vanholder R, Niwa T (2014) Int J Nephrol Renovasc Dis : 49-56
    › Citation · 24501542 (PubMed) · PMC3912158 (PubMed Central)
  2. Hemodialysis: core curriculum 2014. Golper TA, Fissell R, Fissell WH, Hartle PM, Sanders ML, Schulman G (2014) Am J Kidney Dis 63(1): 153-63
    › Citation · 24268927 (PubMed) · PMC4276338 (PubMed Central)
  3. APOL1 risk variants, race, and progression of chronic kidney disease. Parsa A, Kao WH, Xie D, Astor BC, Li M, Hsu CY, Feldman HI, Parekh RS, Kusek JW, Greene TH, Fink JC, Anderson AH, Choi MJ, Wright JT, Lash JP, Freedman BI, Ojo A, Winkler CA, Raj DS, Kopp JB, He J, Jensvold NG, Tao K, Lipkowitz MS, Appel LJ, AASK Study Investigators, CRIC Study Investigators (2013) N Engl J Med 369(23): 2183-96
    › Citation · 24206458 (PubMed) · PMC3969022 (PubMed Central)
  4. Dose-response and efficacy of ferric citrate to treat hyperphosphatemia in hemodialysis patients: a short-term randomized trial. Dwyer JP, Sika M, Schulman G, Chang IJ, Anger M, Smith M, Kaplan M, Zeig S, Koury MJ, Blumenthal SS, Lewis JB, Collaborative Study Group (2013) Am J Kidney Dis 61(5): 759-66
    › Citation · 23369827 (PubMed)
  5. Effects of 6-times-weekly versus 3-times-weekly hemodialysis on depressive symptoms and self-reported mental health: Frequent Hemodialysis Network (FHN) Trials. Unruh ML, Larive B, Chertow GM, Eggers PW, Garg AX, Gassman J, Tarallo M, Finkelstein FO, Kimmel PL, FHN Trials Group (2013) Am J Kidney Dis 61(5): 748-58
    › Citation · 23332990 (PubMed) · PMC4552179 (PubMed Central)
  6. The mitochondrial complex I activity is reduced in cells with impaired cystic fibrosis transmembrane conductance regulator (CFTR) function. Valdivieso AG, Clauzure M, Marín MC, Taminelli GL, Massip Copiz MM, Sánchez F, Schulman G, Teiber ML, Santa-Coloma TA (2012) PLoS One 7(11): e48059
    › Citation · 23185247 (PubMed) · PMC3504030 (PubMed Central)
  7. Tolvaptan in patients with autosomal dominant polycystic kidney disease. Torres VE, Chapman AB, Devuyst O, Gansevoort RT, Grantham JJ, Higashihara E, Perrone RD, Krasa HB, Ouyang J, Czerwiec FS, TEMPO 3:4 Trial Investigators (2012) N Engl J Med 367(25): 2407-18
    › Citation · 23121377 (PubMed) · PMC3760207 (PubMed Central)
  8. In-center thrombolysis for clotted AV access: a cohort review. Umanath K, Morrison RS, Christopher Wilbeck J, Schulman G, Bream P, Dwyer JP (2013) Semin Dial 26(1): 124-9
    › Citation · 22784240 (PubMed)
  9. Rationale and study design of a three-period, 58-week trial of ferric citrate as a phosphate binder in patients with ESRD on dialysis. Umanath K, Sika M, Niecestro R, Connelly C, Schulman G, Koury MJ, Lewis JB, Dwyer JP, Collaborative Study Group (2013) Hemodial Int 17(1): 67-74
    › Citation · 22702490 (PubMed)
  10. Challenges to enrollment and randomization of the Frequent Hemodialysis Network (FHN) Daily Trial. Sergeyeva O, Gorodetskaya I, Ramos R, Schiller BM, Larive B, Raimann JG, Ting GO, Eggers PW, Chertow GM, Levin NW, Frequent Hemodialysis Network Trials Group (2012) J Nephrol 25(3): 302-9
    › Citation · 22505248 (PubMed)